Literature DB >> 22288606

Cytochrome P450 variations in different ethnic populations.

Joseph McGraw1, Donald Waller.   

Abstract

INTRODUCTION: Variability of drug response is an important consideration in clinical medicine. A major determinant of drug response variability is hepatic cytochrome P450 oxidase (CYP450)-mediated drug metabolism. Advances in genetics permits genotyping large numbers of patients to identify single nucleotide polymorphisms (SNPs) which may result in variant CYP450 enzyme expression and/or activity. New SNPs with functional impacts are constantly being identified which further explain variability in CYP450 phenotype. AREAS COVERED: The racial/ethnic distribution of selected CYP450 (CYP1A2, P2C8/9/19, 2D6 and 3A4/5) SNPs are reviewed with an emphasis on the agreement between genotype and phenotype. The reader will gain insight into the SNP distribution by racial/ethnic group and the corresponding relationship between important, highly prevalent, SNPs and their impact on metabolic phenotype. EXPERT OPINION: Racial/ethnic differences in metabolic phenotype can be explained by differences in SNP distribution. However, overlap in substrate specificity, linkage disequilibrium and previously unidentified SNPs have made phenotypic characterization difficult for CYP3A4/5 and 2C8/9. Studies utilizing newly identified, highly prevalent, racially stratified SNPs and their impact on CYP isoform-specific metabolism will provide new answers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22288606     DOI: 10.1517/17425255.2012.657626

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  76 in total

1.  Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.

Authors:  Xiaoxia Wei; Hong Sun; Jie Zhuang; Xiuhua Weng; Bin Zheng; Qiwang Lin; Guifeng Zhang; Jiaqin Cai
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

Review 2.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 3.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 4.  Application of pharmacogenetics in clinical practice: problems and solutions.

Authors:  Andrius Baskys
Journal:  J Neural Transm (Vienna)       Date:  2018-06-19       Impact factor: 3.575

5.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

6.  Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.

Authors:  Taha Ahmad; Samie Sabet; Donald A Primerano; Lauren L Richards-Waugh; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

Review 7.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

8.  PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers.

Authors:  Qing-qing Du; Zhi-jun Wang; Lin He; Xue-hua Jiang; Ling Wang
Journal:  Eur J Clin Pharmacol       Date:  2013-06-27       Impact factor: 2.953

9.  Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.

Authors:  Haiyan Li; Jingchuan Guo; Glenn F Carlson; Renli Teng
Journal:  Br J Clin Pharmacol       Date:  2016-06-09       Impact factor: 4.335

Review 10.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.